RESEARCH STUDY

MVOR-1/MVOR-2: low-dose minocycline vs doxycycline for rosacea (2025)

2025
RCT
653
High

One-line finding

A new low-dose minocycline (40 mg) outperformed both doxycycline 40 mg and placebo for rosacea.

Plain-language summary

These recent trials compared a new low-dose minocycline capsule (DFD-29, now marketed as Emrosi) against low-dose doxycycline and placebo. The minocycline formulation cleared more rosacea bumps and redness, and doxycycline 40 mg also beat placebo, confirming its benefit. This gives context for where doxycycline sits among current rosacea options rather than replacing it.

Citation

Read the study